 | ImaginAb, Inc., a market leading global biotechnology company, and DuChemBio Co., Ltd., a South Korea’s leading radiopharmaceutical company advised by BGM Associates, have recently announced the signing of a Manufacturing and Distribution Partnership to manufacture and supply ImaginAb’s proprietary investigational CD8 ImmunoPET agent Zirconium 89Zr-crefmirlimab berdoxam to pharmaceutical sponsored clinical trials, as well as investigator initiated trials in South Korea. |
The Agreement allows DuChemBio, who operates the largest radiopharmaceutical network in South Korea, to manufacture and distribute the radiotracer for clinical investigations, and to commercialize the product post regulatory approval in South Korea. In addition, the agreement also opens a distribution opportunity for DuChemBio to supply ImaginAb’s CD8-targeting tracers to other Asian countries.
